Quarterly Sales

AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure

AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure

Anika Sharma

The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...